Fig. 2From: Are we creating a new phenotype? Physiological barriers and ethical considerations in the treatment of hereditary transthyretin-amyloidosisBlood–brain barrier. Schematic depiction of the anatomy and function of the blood–brain barrier. ASO, antisence oligonucleotide; JAM, junctional adhesion molecule; RNAi, ribonucleotide acid interference drug. Created with BioRender.comBack to article page